KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Non-Current Liabilities: 2010-2025

Historic Total Non-Current Liabilities for Pacira BioSciences (PCRX) over the last 15 years, with Sep 2025 value amounting to $545.1 million.

  • Pacira BioSciences' Total Non-Current Liabilities fell 27.61% to $545.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $545.1 million, marking a year-over-year decrease of 27.61%. This contributed to the annual value of $754.9 million for FY2024, which is 11.09% up from last year.
  • Per Pacira BioSciences' latest filing, its Total Non-Current Liabilities stood at $545.1 million for Q3 2025, which was down 27.74% from $754.3 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Total Non-Current Liabilities peaked at $1.3 billion during Q4 2021, and registered a low of $545.1 million during Q3 2025.
  • For the 3-year period, Pacira BioSciences' Total Non-Current Liabilities averaged around $706.7 million, with its median value being $715.6 million (2023).
  • As far as peak fluctuations go, Pacira BioSciences' Total Non-Current Liabilities surged by 100.77% in 2021, and later crashed by 36.41% in 2023.
  • Pacira BioSciences' Total Non-Current Liabilities (Quarterly) stood at $1.3 billion in 2021, then tumbled by 31.79% to $878.1 million in 2022, then declined by 22.61% to $679.6 million in 2023, then grew by 11.09% to $754.9 million in 2024, then fell by 27.61% to $545.1 million in 2025.
  • Its last three reported values are $545.1 million in Q3 2025, $754.3 million for Q2 2025, and $764.3 million during Q1 2025.